The evolution of treatment of Ph+ ALL & Phase II study of blinatumomab and ponatinib in Ph+ ALL

Fadi Haddad, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolution of treatment strategies for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), highlighting the rationale, design, and results of a Phase II study evaluating the combination of ponatinib and blinatumomab in newly diagnosed and relapsed/refractory (R/R) patients (NCT03263572). Dr Haddad explains that the advent of tyrosine kinase inhibitors (TKIs) in Ph+ALL and the introduction of blinatumomab has led to a paradigm shift in the treatment of these patients. In particular, the third-generation TKI ponatinib has shown remarkable activity in patients carrying the T315I mutation. Dr Haddad explains that the results of the Phase II trial evaluating ponatinib and blinatumomab are highly promising and have the potential to define this combination as a new standard of care (SOC) that does not involve chemotherapy or stem cell transplantation (SCT). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.